Management of Inflammatory Skin Diseases

Inflammatory skin diseases encompass a broad spectrum of disorders—including psoriasis, atopic dermatitis and rosacea—characterised by dysregulated immune responses, barrier dysfunction and variable microbial influences. Management typically adopts a stratified approach, beginning with topical anti-inflammatory agents such as corticosteroids, calcineurin inhibitors or vitamin D analogues. In moderate to severe cases, systemic therapies—ranging from conventional immunosuppressants to targeted biologics against TNF-α, IL-17 and IL-23—have transformed outcomes. Adjunctive strategies include phototherapy, emollient optimisation and avoidance of recognised triggers. Emerging modalities focus on small-molecule inhibitors (for example JAK and PDE4 inhibitors), modulation of the skin microbiome and personalised interventions guided by advancing molecular and genetic insights. A growing emphasis on safety profiles, long-term adherence and quality of life informs treatment choice globally, driving integration of novel delivery systems and lifestyle interventions to enhance efficacy and reduce adverse events.

Research from Nature Portfolio

Recent studies have uncovered rare deleterious genetic variants in familial forms of rosacea, identifying mutations in genes related to neural synaptic processes and cell adhesion. Functional investigation demonstrated that these variants provoke excessive release of vasoactive neuropeptides from peripheral neurons, precipitating neurogenic inflammation in both human cells and murine models. Such insights into inherited susceptibility and neuro-immune mechanisms open avenues for targeted therapies aimed at modulating neuron-derived inflammatory mediators in chronic cutaneous conditions.

Management of Inflammatory Skin Diseases publication trend

The graph below shows the total number of articles in management of inflammatory skin diseases across all publications each year (not limited to Nature Index journals).

Technical terms

Cytokines: Small signalling proteins released by immune cells that orchestrate inflammation and cell communication.

Keratinocytes: Epidermal cells responsible for forming the skin barrier and participating in immune responses.

mTORC1: Mechanistic target of rapamycin complex 1, a protein complex that regulates cell growth, metabolism and inflammatory signalling.

Nanoformulation: The incorporation of therapeutic agents into nanoscale carriers to enhance skin penetration and target specificity.

Dysbiosis: An imbalance in the normal microbial communities of the skin, often linked to disease initiation or exacerbation.

References

1. Whole genome sequencing identifies genetic variants associated with neurogenic inflammation in rosacea. Nature Communications (2023).
2. Skin-permeable gold nanoparticles with modifications azelamide monoethanolamine ameliorate inflammatory skin diseases. Biomarker Research (2024).
3. Dietary Antioxidants May Support Cosmetic Treatment in Patients with Rosacea. Antioxidants (2024).
4. A positive feedback loop between mTORC1 and cathelicidin promotes skin inflammation in rosacea. EMBO Molecular Medicine (2021).